oncgnostics develops, based on proprietary epigenetic biomarkers molecular tests for reliable cancer diagnostics. This test allows reliable diagnostics of cervical cancer and its pre-stages. Now oncgnostics has raised a seven-digit Euro amount in a Series A financing round.